P. Dapavo

发表

Atopic dermatitis, dupilumab and cancers: a case series

P. Quaglino, S. Ribero, M. Fierro, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience

L. Naldi, A. Costanzo, P. Gisondi, 2020, Journal of Allergy and Clinical Immunology.

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

L. Naldi, K. Peris, C. Guarneri, 2021, Dermatology and Therapy.

Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis

G. Argenziano, G. Fabbrocini, M. Megna, 2020, PloS one.

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study

M. Megna, T. Torres, A. Balato, 2019, The Journal of dermatological treatment.

PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis

L. Naldi, C. G. Egan, P. Malagoli, 2018, The Journal of dermatological treatment.

Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light

C. Casalegno, S. Ribero, P. Dapavo, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

G. Argenziano, N. Balato, K. Peris, 2021, European Journal of Dermatology.

Therapeutic management of chronic spontaneous urticaria in clinical practice: results from a pilot survey

C. Foti, G. Vena, G. Girolomoni, 2022, Italian Journal of Dermatology and Venereology.

Tocilizumab and its usage for skin diseases

P. Quaglino, S. Ribero, M. Fierro, 2022, Italian Journal of Dermatology and Venereology.

TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis

L. Naldi, A. Costanzo, P. Gisondi, 2020, Expert review of clinical immunology.

Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting

G. Fabbrocini, P. Quaglino, V. Bettoli, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

The impact of the COVID‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience

L. Naldi, A. Costanzo, P. Gisondi, 2020, The British journal of dermatology.

Brodalumab treatment in psoriasis patients with severe renal failure

G. Argenziano, V. Conti, S. Ribero, 2021, Italian Journal of Dermatology and Venereology.

Risankizumab shows high efficacy and maintenance in improvement of response until week 52

G. Fabbrocini, M. Megna, P. Quaglino, 2022, Dermatologic therapy.

Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature

P. Gisondi, S. Piaserico, F. Russo, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real‐life Italian tertiary centre experience

P. Quaglino, A. Ramondetta, S. Ribero, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Real life long‐term efficacy and safety of ixekizumab in moderate‐to‐severe psoriasis: A 192 weeks multicentric retrospective study—IL PSO (Italian landscape psoriasis)

G. Argenziano, C. Guarneri, A. Costanzo, 2022, Dermatologic therapy.

Real‐world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real‐life clinical practice) study

G. Argenziano, G. Fabbrocini, M. Megna, 2021, Dermatologic therapy.

Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

K. Peris, A. Costanzo, M. Musumeci, 2021, Acta dermato-venereologica.

The Cost of Psoriasis in Patients under Conventional Systemic Therapy or Biologic: The Results of a Retrospective Analysis Carried out in an Italian Center

R. Ravasio, D. Colombo, E. Zagni, 2018 .

Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy

A. Calcagno, P. Quaglino, S. Ribero, 2022, Acta dermato-venereologica.

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

P. Gisondi, M. Romanelli, G. Schinzari, 2022, Dermatology and Therapy.

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

A. Costanzo, E. Morenghi, A. Narcisi, 2021, Acta dermato-venereologica.

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study

G. Fabbrocini, C. Guarneri, P. Gisondi, 2022, Biomedicines.

The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis.

P. Quaglino, M. Fierro, M. Sanlorenzo, 2016, Journal of the American Academy of Dermatology.

Consensus on the management of patients with psoriatic arthritis in a dermatology setting

I. Olivieri, K. Peris, C. Foti, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

L. Naldi, C. Foti, A. Parodi, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Long-term maintenance treatment of psoriasis: the role of calcipotriol/betamethasone dipropionate aerosol foam in clinical practice

G. Fabbrocini, C. De Simone, P. Calzavara-Pinton, 2021, The Journal of dermatological treatment.

Infantile erythema elevatum diutinum: report of a vesiculo-bullous case.

C. Tomasini, M. Pippione, P. Dapavo, 2006, European journal of dermatology : EJD.

Dual‐targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease

S. Ribero, D. Ribaldone, M. Astegiano, 2020, The Journal of dermatology.

Chilblain acral lesions in the COVID‐19 era. Are they marker of infection in asymptomatic patients?

A. Ramondetta, S. Ribero, M. Fierro, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Immature myeloid precursors in chronic neutrophilic dermatosis associated with myelodysplastic syndrome.

S. Osella-Abate, C. Tomasini, M. Pippione, 2000, The American Journal of dermatopathology.

Combination of dermabrasion and Apremilast for Hailey-Hailey disease

P. Quaglino, T. Deboli, S. Ribero, 2022, Italian Journal of Dermatology and Venereology.

Persistent eruptive lentiginosis in a psoriatic patient after 4‐year effective treatment with ustekinumab

S. Ribero, P. Dapavo, G. Gallo, 2022, Dermatologic therapy.

Long‐term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach

G. Fabbrocini, M. Megna, E. Cagni, 2022, International journal of dermatology.

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study

P. Quaglino, S. Ribero, A. Marzano, 2023, Journal of clinical medicine.

Blockade of Phosphatidylinositol 3-Kinase (PI3K)δ or PI3Kγ Reduces IL-17 and Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis

K. Okkenhaug, H. Ji, E. Hirsch, 2012, The Journal of Immunology.

Psoriasis-like Dermatitis Ameliorates Imiquimod-Induced Reduces IL-17 and γ or PI 3 K δ ( PI 3 K ) Blockade of Phosphatidylinositol 3-Kinase

K. Okkenhaug, E. Hirsch, A. Perino, 2012 .

Efficacy and safety of dimethylfumarate in elderly psoriasis patients: a multicentric Italian study

F. Ricceri, F. Prignano, M. Corazza, 2021, The Journal of dermatological treatment.

Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study *

G. Fabbrocini, K. Peris, G. Casazza, 2020, The British journal of dermatology.

Brodalumab for the treatment of moderate‐to‐severe plaque‐type psoriasis: a real‐life, retrospective 24‐week experience

G. Argenziano, A. Parodi, A. Costanzo, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience

G. Pellacani, P. Amerio, A. Balato, 2019, The British journal of dermatology.

Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study

P. Quaglino, S. Ribero, M. Ortoncelli, 2021, The Journal of dermatological treatment.

Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis.

G. Argenziano, G. Fabbrocini, K. Peris, 2022, Italian journal of dermatology and venereology.

Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks

P. Quaglino, S. Ribero, M. Ortoncelli, 2022, The Journal of dermatological treatment.

Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?

P. Quaglino, S. Ribero, G. Avallone, 2022, Dermatologic therapy.

Elderly psoriatic patients under biological therapies: an Italian experience

M. Romanelli, F. Ricceri, F. Prignano, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Tildrakizumab in real‐life shows good efficacy in moderate‐to‐severe psoriasis regardless of previous use of biologic drugs and joint involvement

P. Quaglino, S. Ribero, M. Ortoncelli, 2022, Dermatologic therapy.

Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real‐life experience in a tertiary referral centre

P. Quaglino, S. Ribero, M. Ortoncelli, 2021, The Australasian journal of dermatology.

Infliximab biosimilar CT‐P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry

P. Gisondi, G. Girolomoni, L. Bianchi, 2017, The British journal of dermatology.

Consensus on the place in therapy of TNF‐α inhibitors in the treatment of patients with chronic plaque psoriasis

P. Gisondi, G. Girolomoni, A. Dattola, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Pression‐induced facial ulcers by prone position for COVID‐19 mechanical ventilation

A. Ramondetta, S. Ribero, P. Dapavo, 2020, Dermatologic therapy.

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study

L. Naldi, P. Gisondi, A. Parodi, 2023, Acta dermato-venereologica.

Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study

G. Argenziano, M. Megna, A. Costanzo, 2023, Vaccines.

Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients

M. Rovaris, G. Canonica, C. Foti, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Management of biological therapies for chronic plaque psoriasis during COVID‐19 emergency in Italy

I. Zalaudek, G. Argenziano, G. Fabbrocini, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series

P. Quaglino, S. Ribero, P. Dapavo, 2022, Acta dermato-venereologica.

Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi Consensus

G. Fabbrocini, P. Amerio, P. Gisondi, 2023, Dermatology and Therapy.

Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study

P. Quaglino, S. Ribero, M. Ortoncelli, 2022, Dermatologic therapy.

Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study

G. Fabbrocini, K. Peris, C. Guarneri, 2023, Advances in therapy.

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

G. Fabbrocini, M. Megna, K. Peris, 2023, Journal of clinical medicine.

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)

C. Guarneri, G. Girolomoni, F. Sampogna, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS)

G. Fabbrocini, M. Megna, C. Guarneri, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study.

M. Megna, T. Torres, A. Balato, 2019, Journal of the American Academy of Dermatology.

Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis

P. Quaglino, S. Ribero, L. Mastorino, 2022, Dermatologic therapy.

Chronic spontaneous urticaria in clinical practice: a pilot survey about attitudes and perceptions on assessment, diagnostic work-up and dietary management

C. Foti, G. Vena, G. Girolomoni, 2022, Italian Journal of Dermatology and Venereology.

Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study

S. Calvieri, L. Losappio, E. Pastorello, 2020, The World Allergy Organization journal.

Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient

P. Quaglino, S. Ribero, L. Tonella, 2020, EJD. European journal of dermatology.

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study

G. Argenziano, G. Fabbrocini, M. Megna, 2021, BMC Health Services Research.

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis

P. Quaglino, S. Ribero, P. Dapavo, 2019, Case reports in dermatology.

Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study

G. Fabbrocini, M. Megna, C. De Simone, 2023, Expert opinion on biological therapy.

Comparison of Secukinumab and Ixekizumab in psoriasis: a real‐life cohort study on the efficacy and drug survival of 445 patients

P. Quaglino, S. Ribero, M. Ortoncelli, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Creation of a severity index for hidradenitis suppurativa that includes a validated quality‐of‐life measure: the HIDRAscore

G. Argenziano, G. Fabbrocini, V. Dini, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

The CANOVA Study Real-World Evidence of Biologic Treatments in Moderate-Severe Psoriasis in Italy: A Gender Perspective

G. Argenziano, G. Fabbrocini, S. Corrao, 2022, Women's health reports.

Certolizumab pegol and its role in pregnancy‐age hidradenitis suppurativa

P. Quaglino, A. Ramondetta, S. Ribero, 2021, International journal of dermatology.

Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?

P. Quaglino, S. Ribero, G. Avallone, 2021, The Journal of dermatological treatment.

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs

P. Quaglino, S. Ribero, L. Mastorino, 2022, Dermatologic therapy.

Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population

P. Quaglino, S. Ribero, G. Avallone, 2022, British Journal of Dermatology.

Risankizumab shows faster response in bio naïve than in bio‐experienced psoriatic patients

P. Quaglino, Fiorella Castelli, S. Ribero, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Adalimumab for the treatment of pediatric psoriasis: a single center experience of 4 cases.

P. Quaglino, S. Ribero, M. Fierro, 2020, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study

A. Costanzo, P. Gisondi, E. Aloisi, 2023, Clinical, cosmetic and investigational dermatology.

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)

G. Argenziano, G. Fabbrocini, M. Megna, 2023, Frontiers in Medicine.

Blockade of Phosphatidylinositol 3-Kinase (PI3K)δ or PI3Kγ Reduces IL-17 and Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis

K. Okkenhaug, H. Ji, E. Hirsch, 2012, The Journal of Immunology.

Exploring Psoriasis Inflammatory Microenvironment by NanoString Technologies

R. Senetta, S. Ribero, L. Mastorino, 2023, Journal of clinical medicine.

PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis

L. Naldi, P. Malagoli, P. Dapavo, 2018, The Journal of dermatological treatment.

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

M. Megna, G. Pellacani, A. Costanzo, 2023, Frontiers in medicine.

New onset sarcoidosis following biologic treatment in patients with seronegative inflammatory arthritis: A case series and systematic literature review.

A. Iagnocco, M. Gatto, C. Lomater, 2023, Autoimmunity reviews.

Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents.

P. Quaglino, S. Ribero, M. Ortoncelli, 2022, Clinical and experimental dermatology.

The Skin Microbiome and Its Role in Psoriasis: A Review

S. Ribero, L. Mastorino, P. Dapavo, 2023, Psoriasis.

The impact of the COVID‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience

L. Naldi, P. Gisondi, S. Cazzaniga, 2020, The British journal of dermatology.

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study

P. Quaglino, S. Ribero, L. Mastorino, 2023, Acta dermato-venereologica.

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

M. Napolitano, S. Ferrucci, A. Narcisi, 2024, Dermatology and therapy.

Alcohol abuse and discretionary habits in psoriatic patients: impact on IL-17 and IL-23 inhibitor response.

S. Ribero, R. Ponti, L. Mastorino, 2024, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Chronic spontaneous urticaria in clinical practice: a pilot survey about attitudes and perceptions on assessment, diagnostic work-up and dietary management.

C. Foti, G. Vena, G. Girolomoni, 2020, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.